Publication Name	World Journal of Nephrology
Manuscript ID	14094
Country	Japan

Received	2014-09-18 09:40
Peer-Review Started	2014-09-18 17:14
To Make the First Decision	2014-10-28 14:25
Return for Revision	2014-11-01 17:41
Revised	2014-11-13 09:41
Second Decision	2014-11-28 14:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-12-10 17:20
Articles in Press	2014-12-10 17:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-01-22 09:04
Publish the Manuscript Online	2015-02-07 09:38

ISSN	2220-6124 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Minireviews
Article Title	Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy
Manuscript Source	Invited Manuscript
All Author List	Hiromichi Suzuki, Tomohiro Kikuta, Tsutomu Inoue and Ukihiro Hamada
Funding Agency and Grant Number
Corresponding Author	Hiromichi Suzuki, MD, PhD, Department of Nephrology and Community Health Science Center, Saitama Medical University, 38 Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan. iromichi@saitama-med.ac.jp
Key Words	Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Dialysis; Chronic kidney disease
Core Tip	The use of renin-angiotensin system (RAS) inhibitors, such angiotensin converting enzyme inhibitors/angiotensin-Ⅱ receptor blockers, to slow progression of chronic kidney disease in a large group dominated by elderly people in the real world is not supported by available evidence. Since it is not clear that progression of kidney disease, and even of proteinuric diabetic nephropathy, is not inhibited through the use of RAS inhibitors, the most patient-centric goal of therapy for many elderly individuals should be individualized.
Publish Date	2015-02-07 09:38
Citation	Suzuki H, Kikuta T, Inoue T, Hamada U. Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy. World J Nephrol 2015; 4(1): 118-126
URL	http://www.wjgnet.com/2220-6124/full/v4/i1/118.htm
DOI	http://dx.doi.org/10.5527/wjn.v4.i1.118

Full Article (PDF)	WJN-4-118.pdf
Full Article (Word)	WJN-4-118.doc
Manuscript File	14094-Review.docx
Answering Reviewers	14094-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14094-Conflict-of-interest statement.pdf
Copyright License Agreement	14094-Copyright assignment.pdf
Peer-review Report	14094-Peer review(s).pdf
Scientific Misconduct Check	14094-CrossCheck.jpg
Scientific Editor Work List	14094-Scientific editor work list.pdf